Gasporox: LTM reacceleration expected in Q1 2025 - Redeye

Redeye provides an update on Gasporox following its Q3 2024 report, which was below expectations but continued net sales growth and positive EBITDA. Redeye revises its estimates and fair value range downward. Redeye expects reacceleration in net sales, which it believes will catalyze the share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1046792/gasporox-ltm-reacceleration-expected-in-q1-2025?utm_source=finwire&utm_medium=RSS